Literature DB >> 1080969

The use of protease inhibitor (trasylol) and heparin in cardiorespiratory resuscitation. I. Studies of the blood clotting system.

W Gaszyński.   

Abstract

The purpose of the study was the assessment of the effect of protease inhibitor (trasylol) and heparin on the blood clotting system during cardiorespiratory resuscitation. The studies were carried out in two experimental groups of rabbits. In group I oxygen was given, cardiac massage was applied, alkalinizing agents and drugs improving the action of the heart and the peripheral circulation were administered. In group II trasylol and heparin were given additionally. The studies proved that cardiorespiratory arrest causes development of the intravascular clotting syndrome. Resuscitation management in group I failed to correct the disturbances in the blood clotting system. On the other hand, in group II they were partly corrected. The animals in this group survived the experiment. The administration of protease inhibitor and heparin increased the efficiency of resuscitation management.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1080969

Source DB:  PubMed          Journal:  Anaesth Resusc Intensive Ther        ISSN: 0301-0864


  3 in total

1.  Thrombolysis using plasminogen activator and heparin reduces cerebral no-reflow after resuscitation from cardiac arrest: an experimental study in the cat.

Authors:  M Fischer; B W Böttiger; S Popov-Cenic; K A Hossmann
Journal:  Intensive Care Med       Date:  1996-11       Impact factor: 17.440

Review 2.  Complement inhibition as a proposed neuroprotective strategy following cardiac arrest.

Authors:  Brad E Zacharia; Zachary L Hickman; Bartosz T Grobelny; Peter A DeRosa; Andrew F Ducruet; E Sander Connolly
Journal:  Mediators Inflamm       Date:  2010-01-26       Impact factor: 4.711

3.  Association of antiplatelet therapy with patient outcomes after out-of-hospital cardiac arrest.

Authors:  Alexandro Gianforcaro; Michael Kurz; Francis X Guyette; Clifton W Callaway; Jon C Rittenberger; Jonathan Elmer
Journal:  Resuscitation       Date:  2017-10-12       Impact factor: 5.262

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.